Rheumatoid Arthritis – Emerging Therapies – Olumiant (Baricitinib) Launch Tracking Wave 1
MARKET OUTLOOK
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak inhibitor, Xeljanz (approved for RA in 2012). With several other Jak inhibitors in late-phase development for RA (e.g., filgotinib [Galapagos/Gilead], upadacitinib [AbbVie]), physicians’ perceptions of Olumiant and the product’s market performance thus far will offer important insight to Eli Lilly and other companies hoping to penetrate this increasingly crowded space. The Rheumatoid Arthritis Emerging Therapy series includes three waves that will track the awareness, trial, and uptake of Olumiant since its U.S. launch in June 2018 for the treatment of RA. In addition, the series will examine anticipated future trends in RA treatment, particularly Olumiant’s uptake, and assess Lilly’s promotional efforts.
QUESTIONS ANSWERED
- What is the awareness of, familiarity with, and perceptions related to Olumiant among U.S. rheumatologists?
- According to surveyed prescribers, to which patients are they prescribing Olumiant, what are the reasons for prescribing the drug, and how satisfied are they with Olumiant?
- How do prescribers and nonprescribers compare across key metrics?
- How are the trial and adoption of Olumiant tracking compared with other recent product launches in the autoimmune market?
PRODUCT DESCRIPTION
Emerging Therapies: is a three-wave series based on primary research data collected at one, six, and twelve months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
GEOGRAPHY
United States
PRIMARY RESEARCH
Survey of 75 U.S. rheumatologists for each wave.
KEY METRICS INCLUDED
- Unaided and Aided Awareness of Olumiant
- Familiarity with and Impressions of Olumiant
- Prescriber and Nonprescriber Profiles
- Willingness to Prescribe Olumiant
- Performance of Olumiant on Key Attributes
- Sales Representative Frequency, Reach, and Satisfaction
- Benchmarking Against Previously Launched Rheumatoid Arthritis Agents
Table of contents
- Rheumatoid Arthritis - Emerging Therapies - Olumiant (Baricitinib) Launch Tracking Wave 1
- Rheumatoid Arthritisu2013Emerging Therapiesu2013Olumiantu2013Wave 1 (September 2018)
Maria Genco, Ph.D., is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her M.S. and Ph.D. in neuroscience from Brandeis University and a B.A. in neuroscience from Wellesley College.
Andrea Kravit is the principal director of the Immune and Inflammatory Disorders team at DRG, part of Clarivate. She oversees a team of analysts and directors conducting patient-based market forecasting, market opportunity assessments, early- to late-phase pipeline analyses, and competitive analytics for the life sciences industry. Ms. Kravit holds a B.A., summa cum laude, from Boston University.